表紙
市場調查報告書

全球搔癢治療藥市場:2017∼2021年

Global Pruritus Therapeutic Market 2019-2023

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 538564
出版日期 內容資訊 英文 81 Pages
訂單完成後即時交付
價格
Back to Top
全球搔癢治療藥市場:2017∼2021年 Global Pruritus Therapeutic Market 2019-2023
出版日期: 將在2019年07月12日內容資訊: 英文 81 Pages
簡介

全球搔癢治療藥市場預計2017∼2021年以4.95%的年複合成長率擴大。各種全身性疾病成為搔癢的原因,引起生物化學性要素的變化和平衡的混亂,導致搔癢。

本報告提供全球搔癢治療藥市場相關調查,市場趨勢與課題,各疾病、各給藥途徑、各地區的趨勢,及加入此市場的主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 調查方法

第4章 簡介

第5章 市場概要

第6章 開發平台環境

第7章 各疾病市場區隔

  • 腎性搔癢
  • 膽汁滯留性搔癢
  • 血液學性搔癢
  • 內分泌性搔癢
  • 腫瘤性搔癢

第8章 各給藥途徑市場區隔

第9章 各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第10章 決策架構

第11章 促進要素與課題

第12章 市場趨勢

  • 新T細胞子集的鑑定
  • 為了產品開發加入新技術
  • 無機成長策略

第13章 供應商環境

  • 競爭模式

第14章 主要供應商分析

  • Allergan
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • 其他關注供應商

第15章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR13976

About Global Pruritus Therapeutic

Pruritus is defined as the unpleasant skin sensation that frequently provokes scratching. Various systemic diseases are the major cause of pruritus. The intensity of sensation ranges from mild to severe. Various diseases cause changes/imbalance of biochemical factors, which trigger skin sensation and lead to pruritus. The market is segmented based on these disease conditions, which are responsible for pruritus.

Technavio's analysts forecast the global pruritus therapeutic market to grow at a CAGR of 4.95% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global pruritus therapeutic market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Pruritus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Allergan
  • GlaxoSmithKline
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Abbott
  • Ajanta Pharma
  • Almirall
  • Astellas Pharma
  • Bristol-Myers Squibb
  • CARA Therapeutic
  • Cipla
  • Eisai
  • Eli Lilly
  • Galderma
  • Glenmark
  • Heron Therapeutic
  • IPCA
  • Lupin
  • Merck
  • Novartis
  • Sun Pharma
  • Takeda Pharmaceutical

Market driver

  • Drug-induced pruritus
  • For a full, detailed list, view our report

Market challenge

  • Poor patient adherence due to inadequate information on drug usage
  • For a full, detailed list, view our report

Market trend

  • Incorporation of novel technology for product development
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market overview

  • Five forces analysis

PART 06: Pipeline landscape

PART 07: Market segmentation by disease type

  • Renal pruritus
  • Cholestatic pruritus
  • Hematologic pruritus
  • Endocrine pruritus
  • Oncological pruritus

PART 08: Market segmentation by route of administration (ROA)

PART 09: Geographical segmentation

  • Pruritus therapeutic market in Americas
  • Pruritus therapeutic market in EMEA
  • Pruritus therapeutic market in APAC

PART 10: Decision framework

PART 11: Drivers and challenges

  • Market drivers
  • Market challenges

PART 12: Market trends

  • Identification of new T-cell subsets (Th17 and Th22)
  • Incorporation of novel technology for product development
  • Inorganic growth strategies

PART 13: Vendor landscape

  • Competitive scenario

PART 14: Key vendor analysis

  • Allergan
  • GlaxoSmithKline
  • Pfizer
  • Sanofi
  • Other prominent vendors

PART 15: Appendix

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Types of pruritus based on causative disease
  • Exhibit 02: Chemical substances that trigger pruritus
  • Exhibit 03: Major diseases that cause pruritus
  • Exhibit 04: Major drug classes that induce pruritus
  • Exhibit 05: Global pruritus therapeutic market drivers
  • Exhibit 06: Global pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 07: Opportunity analysis in global pruritus therapeutic market
  • Exhibit 08: Five forces analysis
  • Exhibit 09: Pipeline molecules based on vendors
  • Exhibit 10: Key clinical trials
  • Exhibit 11: Segmentation of global pruritus therapeutic market by disease type 2016
  • Exhibit 12: Segmentation of global pruritus therapeutic market share by disease type 2016
  • Exhibit 13: Global renal pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 14: Global cholestatic pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 15: Global hematologic pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 16: Global endocrine pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 17: Global oncological pruritus therapeutic market 2016-2021 ($ millions)
  • Exhibit 18: Various ROAs applied for pruritic drugs 2016
  • Exhibit 19: Segmentation of global pruritus therapeutic market by geography 2016 and 2021
  • Exhibit 20: Global pruritus therapeutic market revenue by geography 2016-2021 ($ millions)
  • Exhibit 21: Market scenario in Americas
  • Exhibit 22: Pruritus therapeutic market in Americas 2016-2021 ($ millions)
  • Exhibit 23: Market scenario in EMEA
  • Exhibit 24: Pruritus therapeutic market in EMEA 2016-2021 ($ millions)
  • Exhibit 25: Market scenario in APAC
  • Exhibit 26: Pruritus therapeutic market in APAC 2016-2021 ($ millions)
  • Exhibit 27: Prevalence of pruritus in various disease conditions
  • Exhibit 28: Various drugs responsible for inducing pruritus
  • Exhibit 29: Phase III drugs for management of pruritus
  • Exhibit 30: Global sales of Allegra 2008 and 2016 ($ millions)
  • Exhibit 31: Role of newer T-cell subsets in dermatological diseases
  • Exhibit 32: Inorganic growth strategies
  • Exhibit 33: Competitive structure analysis of global pruritus therapeutic market 2016
  • Exhibit 34: Market penetration of various global pruritus therapeutic manufacturers 2016
  • Exhibit 35: Strategic success factors of companies in global pruritus therapeutic market
  • Exhibit 36: Allergan: Key highlights
  • Exhibit 37: Allergan: Strength assessment
  • Exhibit 38: Allergan: Strategy assessment
  • Exhibit 39: Allergan: Opportunity assessment
  • Exhibit 40: GlaxoSmithKline: Key highlights
  • Exhibit 41: GlaxoSmithKline: Strength assessment
  • Exhibit 42: GlaxoSmithKline: Strategy assessment
  • Exhibit 43: GlaxoSmithKline: Opportunity assessment
  • Exhibit 44: Pfizer: Key highlights
  • Exhibit 45: Pfizer: Strength assessment
  • Exhibit 46: Pfizer: Strategy assessment
  • Exhibit 47: Pfizer: Opportunity assessment
  • Exhibit 48: Sanofi: Key highlights
  • Exhibit 49: Sanofi: Strength assessment
  • Exhibit 50: Sanofi: strategy assessment
  • Exhibit 51: Sanofi: opportunity assessment
Back to Top